Search

Your search keyword '"Kuse, Rolf"' showing total 32 results
Start Over Author "Kuse, Rolf"
32 results on '"Kuse, Rolf"'

4. Fludarabine plus cyclophosphamide is an efficient treatment for advanced chronic lymphocytic leukaemia (CLL): results of a phase II study of the German CLL Study Group

Author

Hallek, Michael, Schmitt, Barbara, Wilhelm, Martin, Busch, Raymonde, Kröber, Alexander, Fostitsch, Hans-Peter, Sezer, Orhan, Herold, Michael, Knauf, Wolfgang, Wendtner, Clemens M., Kuse, Rolf, Freund, Mathias, Franke, Astrid, Schriever, Folke, Nerl, Christoph, Döhner, Hartmut, Thiel, Eckhard, Hiddemann, Wolfgang, Brittinger, Günter, and Emmerich, Bertold

Published
2001

11. Treatment of relapsed or refractory adult acute lymphocytic leukemia

Author

Freund, Mathias, Diedrich, Helmut, Ganser, Arnold, Gramatzki, Martin, Heil, Gerhard, Heyll, Axel, Henke, Michael, Hiddemann, Wolfgang, Haas, Rainer, Kuse, Rolf, Koch, Peter, Link, Hartmut, Maschmeyer, Georg, Planker, Manfred, Queisser, Wolfgang, Schadeck-Gressel, Claire, Schmitz, Norbert, Verschuer, Ulla von, Wilhelm, Sibylla, Thiel, Eckhard, and Hoelzer, Dieter

Subjects
Lymphocytic leukemia, Cancer -- Relapse, Health
Published
1992

12. Major Route Additional Chromosomal Aberrations (ACA) Precede Increase of Blasts in CML: An Analysis of the German CML-Studies III and IIIA

Author

Dietz, Christian T., primary, Fabarius, Alice Charlotte, additional, Lauseker, Michael, additional, Saussele, Susanne, additional, Kalmanti, Lida, additional, Rinaldetti, Sébastien, additional, Haferlach, Claudia, additional, Schlegelberger, Brigitte, additional, Jotterand, Martine, additional, Gratwohl, Alois, additional, Zander, Axel R., additional, Kröger, Nicolaus, additional, Beelen, Dietrich W., additional, Novotny, Jürgen, additional, Nerl, Christoph, additional, Scheid, Christof, additional, Spiekermann, Karsten, additional, Mayer, Jiri, additional, Sayer, Herbert G., additional, Falge, Christiane, additional, Bunjes, Donald, additional, Döhner, Hartmut, additional, Ganser, Arnold, additional, Brossart, Peter, additional, Schwerdtfeger, Rainer, additional, Baumann, Herrad, additional, Kuse, Rolf, additional, Lindemann, Hans Walter, additional, Bormann, Matthias, additional, Hertenstein, Bernd, additional, Baerlocher, Gabriela M., additional, Aul, Carlo, additional, Staib, Peter, additional, Edinger, Matthias, additional, Schatz, Michael, additional, Fauser, Axel A, additional, Arnold, Renate, additional, Hossfeld, Dieter K., additional, Kolb, Hans-Jochem, additional, Schnittger, Susanne, additional, Müller, Martin C., additional, Reiter, Andreas, additional, Hochhaus, Andreas, additional, Pfirrmann, Markus, additional, Hasford, Joerg, additional, Baccarani, Michele, additional, and Hehlmann, Ruediger, additional

Published
2015
Full Text
View/download PDF

27. Treatment of Angioimmunoblastic Lymphadenopathy (AILD)-Type T-Cell Lymphoma Using Prednisone with or without the COPBLAM/IMVP-16 Regimen .

Author

Siegart, Wolfgang, Agthe, Alexander, Griesser, Henrik, Schwerdtfeger, Rainer, Brittinger, Gunter, Engelhard, Marianne, Kuse, Rolf, Tiemann, Markus, Lennert, Karl, and Huhn, Dieter

Subjects
PREDNISONE, LYMPHOMA treatment
Abstract

Provides information on a study that described the clinical course of patients with angioimmunoblastic lymphadenopathy type lymphoma with a sequential treatment with prednisone and COPBLAM/IMVP-16. Methodology of the study; Results and discussion on the study.

Published
1992
Full Text
View/download PDF

29. Improved Outcome in Adult B-Cell Acute Lymphoblastic Leukemia

Author

Hoelzer, Dieter, Ludwig, Wolf-Dieter, Thiel, Eckhard, Gaßmann, Winfried, Loffler, Helmut, Fonatsch, Christa, Rieder, Harald, Heil, Gerhard, Heinze, Barbara, Arnold, Renate, Hossfeld, Dieter, Buchner, Thomas, Koch, Peter, Freund, Matthias, Hiddemann, Wolfgang, Maschmeyer, Georg, Heyll, Axel, Aul, Carlo, Faak, Thomas, Kuse, Rolf, Ittel, Thomas H., Gramatzki, Martin, Diedrich, Helmut, Kolbe, Katrin, Fuhr, Heinz-Georg, Fischer, Konstanze, Schadeck-Gressel, Claire, Weiss, Adelheid, Strohscheer, Imke, Metzner, Bernd, Fabry, Ursula, Gökbuget, Nicola, Völkers, Bernd, Messerer, Dorle, and überla, Karl

Abstract

A total of 68 adult patients with B-cell acute lymphoblastic leukemia (B-ALL) were treated in three consecutive adult muhicenter ALL studies. The diagnosis of B-ALL was confirmed by L3 morphology and/or by surface immunoglobulin (Slg) expression with >25% blast cell infiltration in the bone marrow (BM). They were characterized by male predominance (78%) and a median age of 34 years (15 to 65y) with only 9% adolescents (15 to 20y), but 28% elderly patients (50 to 65y). The patients received either a conventional (N = 9) ALL treatment regimen (ALL study 01/81) or protocols adapted from childhood B-ALL with six short, intensive 5-day cycles, alternately A and B. In study B-NHL83 (N = 24) cycle A consisted of fractionated doses of cyclophosphamide 200 mg/m2for 5 days, intermediate-dose methotrexate (IdM) 500 mg/m2(24 hours), in addition to cytarabine (AraC), teniposide (VM26) and prednisone. Cycle B was similar except that AraC and VM26 were replaced by doxorubicin. Major changes in study B-NHL86 (N = 35) were replacement of cyclophosphamide by ifosphamide 800 mg/m2for 5 days, an increase of IdM to high-dose, 1,500 mg/m2(HdM) and the addition of vincristine. A cytoreductive pretreatment with cyclophosphamide 200 mg/m2, and prednisone 60 mg/m2, each for 5 days was recommended in study B-NHL83 for patients with high white blood cell (WBC) count (>2,500/m2) or large tumor burden and was obligatory for all patients in study B-NHL86. Central nervous system (CNS) prophylaxis/treatment consisted of intrathecal methotrexate (MTX) therapy, later extended to the triple combination of MTX, AraC, and dexamethasone, and a CNS irradiation (24 Gy) after the second cycle. Compared with the ALL 01/81 study where all the patients died, results obtained with the pediatric protocols B-NHL83 and B-NHL86 were greatly improved. The complete remission (CR) rates increased from 44% to 63% and 74%, the probability of leukemia free survival (LFS) from 0% to 50% and 71% (P= .04), and the overall survival rates from 0% to 49% and 51% (P= .001). Toxicity, mostly hematotoxicity and mucositis, was severe but manageable. In both studies B-NHL83 and B-NHL86, almost all relapses occurred within 1 year. The time to relapse was different for BM, 92 days, and for isolated CNS and combined BM and CNS relapses, 190 days (P= .08). The overall CNS relapses changed from 50% to 57% and 17%, most probably attributable to the high-dose MTX and the triple intrathecal therapy. LFS in studies B-NHL83 and B-NHL86 was significantly influenced by the initial WBC count < or >50,000/μL, LFS 71% versus 29% (P= .003) and hemoglobin value > or <8 g/dL, LFS 67% versus 27% (P= .02). Initial CNS involvement had no adverse impact on the outcome. Elderly B-ALL patients (>50 years) also benefited from this treatment with a CR rate of 56% and a LFS of 56%. It is concluded that this short intensive therapy with six cycles is effective in adult B-ALL. HdM and fractionated higher doses of cyclophosphamide or ifosphamide seem the two major components of treatment.

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results